Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer
Du, Fangyu; Zhou, Qifan; Shi, Yajie; Yu, Miao; Sun, Wenjiao; Chen, Guoliang. A new pathway via intermediate 4-amino-3-fluorophenol for the synthesis of regorafenib. Synthetic Communications. Volume 49. Issue 4. Pages 576-586. Journal; Online Computer File. (2019).
Research on Chemical Intermediates Volume 42 Issue 4 Pages 3209-3218 Journal; Online Computer File 2016
Liu, Zhenteng; Liu, Xinquan; Wei, Shuhong; Gao, Ruizhao. Method for preparing regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., Peop. Rep. China. CN 108558747. (2018).
: Oruganti, Srinivas; Rapolu, Rajesh Kumar. Processes for the preparation of diphenyl urea derivatives and novel intermediates thereof. Assignee Dr. Reddy's Laboratories Limited, India. IN 2014CH01136. (2016).
Sun, Song; Li, Qiang; Hou, Xiaolong. Preparation method of Regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Co., Ltd., Peop. Rep. China. CN 105330600. (2016).
Xu, Qiang; Huang, Shuang; Yang, Jian; Wang, Ping; Xia, Bin; Qian, Gang. Process for the preparation of regorafenib. Assignee Jiangsu Zhongbang Pharmaceutical Co., Ltd., Peop. Rep. China. CN 105130887. (2015).
